{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117217","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.638773+00:00","generated_at":"2026-05-30T00:53:36.238498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Leap Therapeutics Q3 net loss $18.2M; DKN-01 CRC enrollment complete, data mid-2025","bullets":["Net loss of $18.2M for Q3 2024, up from $13.7M YoY, driven by higher R&D expenses.","R&D expenses $14.9M (vs $11.5M); G&A $2.9M (vs $3.3M); cash $62.8M at Sept 30, 2024.","Completed enrollment (188 patients) in Part B of DeFianCe study (DKN-01 in CRC); initial data expected mid-2025.","DisTinGuish study (GEJ/gastric) Part C follow-up ongoing; initial data late 2024 or early 2025.","Initiated development of FL-501, an anti-GDF-15 antibody for cachexia; promising preclinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117217","json":"https://secwatch.observer/filing/0001104659-24-117217.json","markdown":"https://secwatch.observer/filing/0001104659-24-117217.md","text":"https://secwatch.observer/filing/0001104659-24-117217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/0001104659-24-117217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/tm2428221d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:53:36.238498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}